The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blum-Tirouvanziam, U.
Right arrow Articles by Corradin, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blum-Tirouvanziam, U.
Right arrow Articles by Corradin, G.

The Journal of Immunology, Vol 154, Issue 8 3922-3931, Copyright © 1995 by American Association of Immunologists

ARTICLES

Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum

U Blum-Tirouvanziam, C Servis, A Habluetzel, D Valmori, Y Men, F Esposito, L Del Nero, N Holmes, N Fasel and G Corradin
Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland.

Localization of human MHC class I-restricted T cell epitopes in the circumsporozoite (CS) protein of the human parasite Plasmodium falciparum is an important objective in the development of antimalarial vaccines. To this purpose, we synthesized a series of overlapping synthetic 20-mer peptides, spanning the entire sequence of the 7G8 CS molecule except for the central repeat B cell domain. The P.f.CS peptides were first tested for their ability to bind to the human MHC class I HLA-A2.1 molecule on T2, a human cell line. Subsequently, the use of a series of shorter peptide analogues allowed us to determine the optimal A2.1 binding sequence present in several of the 20-mers. Binding P.f.CS peptides were further tested for their capacity to activate PBL from HLA-A2.1+ immune donors living in a malaria-endemic area. Specific IFN-gamma production was detected in the supernatant of cultures of PBL from exposed individuals. Cytotoxic T cell lines and clones were derived from the PBL of one responder, and their activity was shown to be HLA-A2.1-restricted and specific for the peptide 334- 342 of the CS protein. In addition, double transgenic HLA-A2.1 x human beta 2-microglobulin mice were immunized with peptide 1-10 of the CS protein. T cells derived from immune lymph nodes displayed a peptide- specific HLA-A2.1-restricted cytolytic activity after one in vitro stimulation.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. L. Slingluff Jr., G. R. Petroni, K. A. Chianese-Bullock, M. E. Smolkin, S. Hibbitts, C. Murphy, N. Johansen, W. W. Grosh, G. V. Yamshchikov, P. Y. Neese, et al.
Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting
Clin. Cancer Res., November 1, 2007; 13(21): 6386 - 6395.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
K. E. Lyke, R. B. Burges, Y. Cissoko, L. Sangare, A. Kone, M. Dao, I. Diarra, M. A. Fernandez-Vina, C. V. Plowe, O. K. Doumbo, et al.
HLA-A2 Supertype-Restricted Cell-Mediated Immunity by Peripheral Blood Mononuclear Cells Derived from Malian Children with Severe or Uncomplicated Plasmodium falciparum Malaria and Healthy Controls
Infect. Immun., September 1, 2005; 73(9): 5799 - 5808.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. V. Yamshchikov, D. W. Mullins, C.-C. Chang, T. Ogino, L. Thompson, J. Presley, H. Galavotti, W. Aquila, D. Deacon, W. Ross, et al.
Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma
J. Immunol., June 1, 2005; 174(11): 6863 - 6871.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. A. Chianese-Bullock, J. Pressley, C. Garbee, S. Hibbitts, C. Murphy, G. Yamshchikov, G. R. Petroni, E. A. Bissonette, P. Y. Neese, W. W. Grosh, et al.
MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma
J. Immunol., March 1, 2005; 174(5): 3080 - 3086.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Slingluff Jr, G. R. Petroni, G. V. Yamshchikov, S. Hibbitts, W. W. Grosh, K. A. Chianese-Bullock, E. A. Bissonette, D. L. Barnd, D. H. Deacon, J. W. Patterson, et al.
Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule
J. Clin. Oncol., November 15, 2004; 22(22): 4474 - 4485.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
H. Shams, P. F. Barnes, S. E. Weis, P. Klucar, and B. Wizel
Human CD8+ T cells recognize epitopes of the 28-kDa hemolysin and the 38-kDa antigen of Mycobacterium tuberculosis
J. Leukoc. Biol., December 1, 2003; 74(6): 1008 - 1014.
[Abstract] [Full Text]

Home page
 Infect. Immun.Home page
L. C. Gavrilescu and E. Y. Denkers
Apoptosis and the Balance of Homeostatic and Pathologic Responses to Protozoan Infection
Infect. Immun., November 1, 2003; 71(11): 6109 - 6115.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Slingluff Jr., G. Yamshchikov, P. Neese, H. Galavotti, S. Eastham, V. H. Engelhard, D. Kittlesen, D. Deacon, S. Hibbitts, W. W. Grosh, et al.
Phase I Trial of a Melanoma Vaccine with gp100280-288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes
Clin. Cancer Res., October 1, 2001; 7(10): 3012 - 3024.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. H. Nardin, J. M. Calvo-Calle, G. A. Oliveira, R. S. Nussenzweig, M. Schneider, J.-M. Tiercy, L. Loutan, D. Hochstrasser, and K. Rose
A Totally Synthetic Polyoxime Malaria Vaccine Containing Plasmodium falciparum B Cell and Universal T Cell Epitopes Elicits Immune Responses in Volunteers of Diverse HLA Types
J. Immunol., January 1, 2001; 166(1): 481 - 489.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
M. Aidoo, A. Lalvani, S. C. Gilbert, J. T. Hu, P. Daubersies, N. Hurt, H. C. Whittle, P. Druihle, and A. V. S. Hill
Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and Other HLA Types in the Malaria Vaccine Candidate Liver-Stage Antigen 3
Infect. Immun., January 1, 2000; 68(1): 227 - 232.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. R. Reynolds, E. Celis, A. Sette, R. Oratz, R. L. Shapiro, D. Johnston, M. Fotino, and J.-C. Bystryn
HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients
J. Immunol., December 15, 1998; 161(12): 6970 - 6976.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
R. Wang, D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. R. Jones, P. Hobart, M. Margalith, J. Ng, et al.
Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine
Science, October 16, 1998; 282(5388): 476 - 480.
[Abstract] [Full Text]

Home page
 NEJMHome page
J. A. Stoute, M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garcon, U. Krzych, M. Marchand, et al.
A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against Plasmodium falciparum Malaria
N. Engl. J. Med., January 9, 1997; 336(2): 86 - 91.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.